UnitedHealth Group’s adjusted net earnings plunged 41% year over year in 2025, falling from $34.4 billion to $21.7 billion. The decline was driven by rising medical cost trends, a $799 million net impact from a major cyberattack and $2.521 billion in restructuring and related charges. Management has forecast modest recovery, targeting $24 billion in adjusted earnings by 2026, but projects operating cash flow will contract to $18 billion, down from $22 billion in 2025. This combination of margin compression and cash flow reduction has contributed to a share price decline of more than 40% over the past three years, underscoring elevated near-term risks for investors.

Despite recent headwinds, UnitedHealth’s dividend payout appears well supported. With a 3.1% forward yield, the annual dividend obligations are substantially covered by projected cash flows, even at the conservative $18 billion level for 2026. Valuation multiples have come down significantly: the trailing P/E ratio of 17.5x sits roughly 17% below the five-year average, while the price-to-sales ratio of 0.58x is more than 55% beneath its historical norm. These metrics suggest the market is pricing in continued pressures, yet they also signal a potential margin of safety for income-seeking investors.

UnitedHealth’s 2025 revenue grew 12% to $447.6 billion, and management is guiding for revenue above $439 billion in 2026. By leveraging AI initiatives to streamline administrative costs, targeting long-term earnings growth of 13–16%, and aligning with shareholders through significant insider share purchases, the company is positioning for a multi-year rebound. Additionally, a modest 0.09% proposed increase in Medicare Advantage reimbursement rates for 2027—UnitedHealth’s largest business segment in 2025—may represent a near-term headwind, but could prove temporary. Contrarian investors may view current levels as an attractive entry point for a potential recovery through 2030.